Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05709314 · ClinicalTrials.gov registry record · Phase 2
A Study of AMDX-2011P in Participants With CAA
A Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Amydis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05709314: Recruiting Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Amydis.
NCT05709314 is a Phase 2 study of Cerebral Amyloid Angiopathy that is actively recruiting participants, run by Amydis. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05709314, a Phase 2 study of Cerebral Amyloid Angiopathy, is actively recruiting participants, sponsored by Amydis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Primary Outcome
Incidence, nature and severity of AEs/SAEs
Conditions Studied
Interventions
- DRUG AMDX-2011P
Study Locations (1)
Arizona
- Associated Retina Consultants - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05709314 shows while recruiting
NCT05709314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Cerebral Amyloid Angiopathy appearing as the primary indexed condition, and to 1 intervention - of which AMDX-2011P is the first listed.
NCT05709314 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05709314 about?
NCT05709314 is a clinical study titled "A Study of AMDX-2011P in Participants With CAA". The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
What is the current status of trial NCT05709314?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-07-09. Estimated completion is 2026-12.
What conditions does trial NCT05709314 study?
This clinical trial studies the following conditions: Cerebral Amyloid Angiopathy.
What interventions are being tested in trial NCT05709314?
The interventions under investigation include: AMDX-2011P (DRUG).
Who is sponsoring clinical trial NCT05709314?
This trial is sponsored by Amydis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05709314 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Amyloid Angiopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05709314's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI